2017 September Presentation
(Warning: The followings are generally quoted from this presentation based on my understanding, which may not be accurate. Please read the presentation by yourself for the details.)
iCo-008:
Out-licensed systemic uses to Immune Pharmaceuticals
-
$500,000 USD upfront payment;
-
Max. $32,000,000 USD in potential milestones;
-
654,486 shares & 123,649 warrants;
-
Royalties on net sales;
-
Retain WW rights to ocular indications.
Phase2 clinical data (UC, BP) completion in H1 2018.
OralAmphotericin:
-
Significant and growing intellectual property base (12 issued patents to date).
-
AmBisome®, $388M in sales 2014.
-
Unmet need: oral formulation.
-
Potential to deliver other highly insoluble assets in carrier system.
A Phase 1, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose Administration of Oral Amphotericin B in Healthy Volunteers
-------------------------------------------------------------
By the way, ICO will give a presentation at 19th Annual Global Investment Conference. Please see the website at:
Hopefully, something good will come out from this conference.
I personally think ICO has very strong fundamentals with great potential.
Quote by Warren Buffett: “Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Always do your own due diligence and invest wisely.